SPECIALTY PHARMACEUTICALS
INJECTABLES | GENERICS
The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services. Jubilant’s success is an outcome of strategic focus on the pharmaceuticals and life sciences industry, moving up the value chain for products and services across geographies, constantly investing in various growth platforms and promoting a culture of innovation.

The Company is engaged in continuous improvement of products and processes to enhance the quality of production and cost competitiveness in order to build value for its customers. Jubilant Life Sciences serves its customers globally with sales in over 100 countries and ground presence in India, North America, Europe, Singapore and China. The Company is recognised as a Partner of Choice by leading life sciences companies worldwide. Jubilant has relationships with 19 of Top 20 pharmaceutical companies and 7 amongst Top 10 agrochemical companies across the globe.

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries.

The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services.

Jubilant’s success is an outcome of strategic focus on the pharmaceuticals and life sciences industry, moving up the value chain for products and services across geographies, constantly investing in various growth platforms and promoting a culture of innovation.

The Company is engaged in continuous improvement of products and processes to enhance the quality of production and cost competitiveness in order to build value for its customers. Jubilant Life Sciences serves its customers globally with sales in over 100 countries and ground presence in India, North America, Europe, Singapore and China. The Company is recognised as a Partner of Choice by leading life sciences companies worldwide. Jubilant has relationships with 19 of Top 20 pharmaceutical companies and 7 amongst Top 10 agrochemical companies across the globe.
Over the years, Jubilant Life Sciences has extended its footprint beyond India in the USA, Canada, Europe, Singapore, China and other countries across the globe. It has also expanded the business by building capabilities internally, through strategic expansions and acquisitions. Jubilant’s multi-location presence helps in getting closer to customers and serving them better with best in class products developed most efficiently, economically with speed to market.

Jubilant Life Sciences' progress in diverse businesses has been made possible through the contribution of R&D; for quality, non-infringing process for product development and cost reduction through process innovation. Innovation at Jubilant is backed by strong chemistry, bio science expertise and the knowledge bank created over the years. The Company has harnessed its strengths - a strong R&D team, modern R&D facilities, command over better technologies and economies of scale into a synergistic organic entity, continuously creating and nurturing high quality products and technologies.

In line with Jubilant Life Sciences continued focus on sustainability of business, the Company aims at improving stakeholder value through improved eco efficient use of capital and natural resources. Jubilant’s approach to sustainable development focuses on the triple bottom line of Economics, Environment and Social performance. The Company is committed and working in various areas for energy conservation and climate change mitigation. Jubilant Life Sciences’ sustainability efforts have been reported through a Corporate Sustainability Report since 2003 and this report received GRI G3.A+ application level & GRI (FY 2007- FY 2015 ), from FY 2016 the company publishes this report in line with latest GRI G4 guidelines assured by E&Y. This reflects Jubilant’s commitment towards sustainable development and continued efforts directed towards protecting the environment wherever it operates.

Corporate Social Responsibility is an integral part of how Jubilant Life Sciences conducts business and how the efforts are directed towards community development through focus on primary education, basic healthcare service, and livelihood generation programs focused on improving the employability of women and local youth.

The Company has been recognised with several awards and recognitions, which bear testimony to its commitment towards operational excellence, innovation, corporate governance and social responsibility.

Jubilant Life Sciences is committed to leverage innovation and scale of operations at every step to deliver value to its stakeholders.
Overview

Jubilant Pharma is driven by the motive to add value to millions of lives through innovations and cutting-edge technology. With the continuous expansion of nearly four decades and the drive for excellence it has attained leadership positions in the key businesses we operate in.

Jubilant Pharma Business is Radiopharmaceuticals, CMO of Sterile Injectables, Allergy Therapy products, Solid Dosage Formulations, Active Pharmaceuticals Ingredients and India Branded Pharmaceuticals.

The Company is one of the leading manufacturers in all the above segments.

BUSINESS HIGHLIGHTS

- Serving customers in over 65 countries.
- Partners 19 out of the top 20 pharmaceutical companies.
- 4 manufacturing locations in North America and 2 in India.
- International regulatory approvals by leading authorities such as US FDA, UK MHRA, ANVISA Brazil, PMDA Japan, AFSSAPS France, ANSM, TGA, COFEPRIS and others.
JUBILANT PHARMA
LEADERSHIP POSITIONS

GENERICS
No. 1 in US in 2 products and ranked among top 3 in 6 products
Globally No. 1 in 4 APIs and ranked among top 3 in 3 APIs

ALLERGY IMMUNOTHERAPY
Among top 3 suppliers in North America

RADIOACTIVE PHARMACEUTICALS
No. 1 in North America in 3 Nuclear Medicine products

CONTRACT MANUFACTURING
Among top 5 contract manufacturers in North America in Sterile Injectables

BUSINESS AROUND THE WORLD
JUBILANT PHARMA

INDIA
Noida, Uttar Pradesh
Office
R&D Centres

Nanjangud, Karnataka
US FDA, AFSSAPS France & PMDA ANSM, TGA, ANVISA, COFEPRIS, approved API Facilities

Roorkee, Uttarakhand
US FDA, UK MHRA, ANVISA Brazil and PMDA Japan approved facility for Generics (Tablets & Capsules)

NORTH AMERICA
Yardley, Pennsylvania, USA
Jubilant Life Sciences US Office

Horsham, Pennsylvania, USA
Jubilant Cadista - Sales & Marketing

Kirkland, Quebec, Canada
US FDA approved facility for Contract Manufacturing of Sterile Injectables and Radiopharmaceuticals

Salisbury, Maryland, USA
US FDA approved facility for Generics (Tablets and Capsules)

SPOKANE, Washington, USA
US FDA approved facility for Contract Manufacturing of Sterile Injectables and Allergy Therapy Products

SINGAPORE
Jubilant Pharma Limited
Corporate Office

EUROPE
Merelbeke, Belgium
Generic Marketing

CHINA
Shanghai, China
Marketing Office

DRUG DISCOVERY SOLUTIONS

INDIA
Bengaluru, Karnataka
State-of-art Discovery Centre
WHY JUBILANT PHARMA

Jubilant Pharma nurtures innovations, offers excellent quality and always stretches to inspire confidence in its customers.

R&D

- Around 1000 qualified and well-experienced scientists positioned in state-of-art R&D Centers located in North America, Noida and Bengaluru, specialize in Pharma research.
- Well equipped facilities that meet global standards and are accredited by major international regulatory authorities that support research and development pertaining to Generics & Specialty Pharmaceuticals.
- The R&D team also aids in avoiding any potential infringement on third party’s intellectual property by developing research strategies as well as better understanding of emerging threats and identifying newer opportunities.

Business Excellence

- Initiatives cover all facets of the business including Manufacturing, Sales and Marketing, New Product Introduction (R&D), Supply Chain, Corporate HR, Projects and other support functions which help in creating a more efficient value chain through Six Sigma, Lean, Design for Six Sigma, World Class Manufacturing (WCM), Total Productivity Management (TPM), Supply Chain Re-engineering (SCOR), Project Management (EPM), Operation Research and Business Intelligence (BI) and plant performance evaluation through Overall Process Effectiveness.
- Maynard Operation Sequencing Technique (MOST) for manpower productivity enhancement and Dynamic and Steady State Simulation Modeling for enhancing efficiencies of processes using tools like ASPEN and DYNOCHEM.
- Capacity debottlenecking projects through application of Lean Six Sigma and process simulation in APIs, Solid Dosage Formulations, Supply Chain re-engineering solutions in the areas of planning and sourcing.
- Cash to Cash cycle time reduction and working capital improvements were driven across all businesses by following best in class Lean and Supply Chain practices.

Climate Change

- Climate Change Mitigation Policy and Green Supply Chain Policy of Jubilant sets the strategic tone to align its business activities to reduce its climate change impact through reduced carbon footprint.
- Voluntary participation in Carbon Disclosure Project (CDP) to publicly demonstrate its Greenhouse Gas emission performance and commitment.
- Emphasis on use of renewable energy sources like biogas, bio-mass, bio-diesel in its energy mix to reduce carbon footprint.
- Dedicated Business Excellence (BE) team to identify, plan, budget, implement, monitor and report all energy consumption reduction and efficiency improvement projects every year.
- Conducted two life cycle based (Cradle to Gate) carbon footprint studies of key products in 2010-11 and in 2011-12.

Employee Health and Safety

- Safety of employees at workplace is of prime importance and linked to KRA of the top management. EHS policy reflects safety commitment of the Company.
- OHSAS 18001 certified Manufacturing plants with occupation health centers run by occupational health physicians.
- Company is signatory to Responsible Care of Indian Chemical Council (ICC).
- Behavioral Based Safety (BBS) program in all Indian Manufacturing locations in 2013.
- Safety performance of the Company is communicated publicly through its annual sustainability report in addition to regular reporting to regulatory bodies in line with local regulation.

Customer Health and Safety

- Strong team involving R&D, QA, QC, sales and marketing to take care of product safety.
- GMP approval for Indian market, AFSSAPS (France), PMDA (Japan), KFDA (Korea), COFEPRIS (Mexico), ANVISA (Brazil) and TGA (Australia) approvals are there for exporting products to relevant countries.
- Being primarily in B2B business the Company adheres to the transport labels governed by IATA for shipments by Air, IMDG for shipments by the Sea and ADR for transportation by road.
- Committed to sustainable operations, Jubilant Life Sciences is now Responsible Care®14001:2013 certified under the American Chemistry Council’s (ACC) Responsible Care® program for its Corporate Office, Noida and for the Manufacturing Unit Gajraula.
Jubilant DraxImage develops, manufactures and commercializes Radiopharmaceuticals used for the diagnosis and treatment of diseases. The company serves markets globally, and is the market leader in North America in three Nuclear Medicine segments. Clinical applications include diagnostic imaging for Cardiology, Oncology, Lung, Kidney, Brain and Bone, as well as Radiotherapy for Thyroid and Cancer. The Company has a strong new product development pipeline in particular for Rubidium Rb - 82 (a Rubidium Generator, for PET Cardiology) and Generic products.

Jubilant HollisterStier CMO is an integrated Contract Manufacturing Organisation manufacturing Sterile Injectables and Non-sterile products. Its contract manufacturing facilities are located across North America & India and provide specialized manufacturing services for global leaders in the pharmaceutical and biopharmaceutical industries.

HollisterStier Allergy, a business unit of Jubilant Pharma has been a leader in the United States immunotherapy industry for more than 90 years. Over these years the company has expanded its customer base to include allergists, ENT doctors and clinics, primary care physicians, hospitals, and pharmacies in the US, Canada, Australia and many other international markets. It currently has over 200 allergenic extracts and mixes and a line of specialised skin test devices in the market.

Innovation is a tradition at Jubilant. Continuous focus on product innovation enables the company to offer doctors the requisite tools needed to treat and cure patients suffering from the effects of allergies.
GENERICS

SOLID DOSAGE FORMULATIONS
Jubilant Generics, a subsidiary of Jubilant Pharmaceuticals, partners global pharmaceutical companies in an endeavor to offer cost effective Generics with speed to market. The Generics business is backward integrated into APIs business of the company and focuses on manufacturing & sale of proprietary Dosage Formulations including CVS, CNS and Anti-allergy categories.

The company has 90 filed ANDAs in US (86 Oral & 4 Sterile), 100 filings in Europe, 22 filings in Canada and over 680 filings in other countries across the world.

ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
Jubilant Generics, a subsidiary of Jubilant Pharmaceuticals, has 39 commercial APIs focusing on CVS, CNS, Anti-infective and Anti-ulcerants, which are marketed to leading Generics companies. Jubilant’s forward integration into Generics, 89 US DMFs, 14 JDMFs, 41 CEPs to its credit and excellent track record has given the Company momentum in key markets like North America, South America, Europe, Japan, Korea, Middle East and Australia.

INDIA BRANDED PHARMACEUTICALS:
Jubilant branded generics is targeting the domestic formulations market in India through this business. The chosen therapeutic areas include chronic specialty segments like Cardiology and Diabetes underlined by combination of enabling growth factors, including higher awareness, longer life spans, enhanced propensity to spend and evolving lifestyles.

This is supported by an extensive distribution network covering 25,000 retail points and robust field force of more than 400 sales representatives that service 25,000 Cardiologists, Diabetologists, Nephrologists, Neurologists and Consulting Physicians spread across the country.

DRUG DISCOVERY SOLUTIONS (DDS)
Drug Discovery Solutions of Jubilant Life Sciences Ltd.
The two verticals, Jubilant Biosys and Jubilant Chemsys offer end to end integrated discovery solutions spanning Target Identification / Target Validation, Lead Optimization / Preclinical candidate across therapeutic areas including Oncology, Metabolic Disorders, CNS, Pain, Inflammation, Fibrosis and Respiratory diseases. The Company uses a customized approach to offer innovative solutions across the Drug Discovery value chain to service the Biotechnology and Pharmaceutical Industry.
Jubilant’s promise of Caring, Sharing, Growing finds life in each of the many endeavors we have been consistently implementing. We take pride in our long and momentous journey of caring for our environment, people and partners.

Jubilant’s approach to sustainable development focuses on the Triple Bottom Line of Economic, Environmental and Social Performance. It follows a structured methodology for risk identification and management. Our Corporate Sustainability Program has been recognized by institutions like Global Reporting Initiative (GRI), International Finance Corporation (IFC), Confederation of Indian Industry (CII), Associated Chambers of Commerce & Industry of India (ASSOCHAM) and Federation of Indian Chambers of Commerce & Industry (FICCI).

### Caring for the Environment
- Follows precautionary approach & 3R (Reduce-Recycle-Reuse) principles across business verticals and processes.
- Set 2020 environment target to reduce specific water & energy consumption and specific Greenhouse Gas (GHG) emission by 12% against 2012-13 performance.

### Sharing With the Community
- Empowers community through development initiatives in the realm of Education, Health and Livelihood. The social programs reach to 100 Rural Government Primary schools through enhancing quality of education, 450,000 people through basic healthcare programs and around 2000 youths through Vocation Training Centers.
- Partners with CII for Food and Agriculture Centre for Excellence (FACE).
- Confers The Social Entrepreneur of the Year India Award in collaboration with the Schwab Foundation (sister organisation of World Economic Forum) to identify and encourage visionary social entrepreneurs.

### Growing Sustainably
- Signatory to UNGC (United Nation Global Compact) & follows the principle of Human Rights at workplace.
- Instituted Ombudsman Office to take care of any form of Human Rights violation at workplace.
- Voluntary participating member in CDP (Carbon Disclosure Project)
- Committed to sustainable operations, Jubilant Life Sciences is now Responsible Care®14001:2013 certified under the American Chemistry Council’s (ACC) Responsible Care® program for its Corporate Office, Noida and for the Manufacturing Unit Gajraula.
- Active member of GRI South Asia Consortium from chemical sector and longtime member in GRI Gold Community
- Publishing Corporate Sustainability Report since 2003 and this report received GRI G3.1 A+ Application level & GRI Check (FY2007 – FY 2015), from FY 2016 the company publishes this report in line with latest GRI G4 guidelines assured by E&Y.
AWARDS & RECOGNITIONS

- 'Most Consistent IR (Investor Relations) Practice in the country' Award for the year 2017 instituted by IR Society of India
- Green tech Environment Award 2017 received by Nanjangud Plant.
- Jubilant Life Sciences Ltd, Gajraula awarded with CII 17th National Award for Excellence in Energy Award 2016 In Category of Chemical/Pharma/Fertilizers
- Jubilant Life Sciences Ltd, Gajraula is awarded ICC certificate of merit 2016 for the continuous efforts of 'water resources management in chemical industries'
- Gold Award to Bharuch site for Best Kaizen Award 2016 (ACCQC) competition organized by Quality Circle Forum of India (QCFI) in Ankleshwar.
- Safety Award 2016 by National Safety Council received by Nira Plant
- Safety Innovation Award 2016 by The Institution of Engineers (India) received by Nanjangud plant
- FICCI Chemicals & Petrochemicals Awards' 2016 Award - 'Sustainability Award for Green Process' in Chemical Sector.
- Excellence in Skill Development Award for the Year 2016 by PHD Chamber of Commerce and Industry
- Golden Peacock Business Excellence Award-2014, recognized under the 'Chemicals and Pharmaceutical category', presented by Hon’ble Governor of Tamil Nadu, K. Rosaiah to our Gajraula plant, India
- Golden Peacock National Quality Award for Quality, Training, Business Excellence and Innovative Product / Service 2015, presented at Dubai Global Convention, organized by Institute of Directors
- 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under Chemicals and Pharmaceutical sector - Gajraula plant, India
- Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC) competition organized by Quality Circle Forum of India (QCFI), Ankleshwar presented to our Bharuch plant, India
- Uththama Suraksha Puraskara from National Safety Council, Karnataka Chapter - Nanjandgud Plant, India
- Two Awards at UBM India Pharma Awards 2014: Excellence in Corporate Social Responsibility & Excellence in Environment, Health & Safety (EHS)
- CII Energy Efficient Unit Award 2014, conferred to our Gajraula Plant, India
- I.C.O.N.I.C IDC Insights Award, under ‘Health and Life Sciences’ vertical